Reunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare Investor Conference
April 25, 2023 07:35 ET
|
Reunion Neuroscience Inc.
TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
April 25, 2023 07:30 ET
|
Reunion Neuroscience Inc.
TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors
April 03, 2023 07:30 ET
|
Reunion Neuroscience Inc.
- Seasoned Psychiatrist and Global Pharmaceutical R&D Executive with Over Two Decades of Experience in Clinical Development, Including at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb and...
Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting
March 27, 2023 07:30 ET
|
Reunion Neuroscience Inc.
TORONTO, March 27, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Files Lawsuit Against Mindset Pharma
March 13, 2023 18:52 ET
|
Reunion Neuroscience Inc.
TORONTO, March 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference
March 07, 2023 07:30 ET
|
Reunion Neuroscience Inc.
TORONTO, March 07, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results
February 14, 2023 07:30 ET
|
Reunion Neuroscience Inc.
Company Completed Phase 1 Interim Data Analysis for Lead Asset, RE104, Which Showed Strong Safety and Tolerability with Differentiated Profile; Final Data Anticipated in Mid-2023 Continued to...
Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET
February 02, 2023 07:30 ET
|
Reunion Neuroscience Inc.
TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and...
Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer
January 18, 2023 07:30 ET
|
Reunion Neuroscience Inc.
TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and...
Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104
January 09, 2023 07:30 ET
|
Reunion Neuroscience Inc.
TORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and...